1Kinlen L. In immunolgic factors, including AIDS. Sehotterdeld D,Fraumeni JF, eds. Cancer epidemiology and prevention, 2nd edn.New York, Oxford University Press, 1996. 532-545.
2IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human immunodeficiency viruses and human T-cell lymphotropic viruses. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 67. Lyon, IARC, 1996.
3CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR, 1987,36(S-1) : 1.
4CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR, 1993,41(RR-17) : 1.
5Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet,1998,351:1833-1839.
6Biggar RJ, Frisch M, Goedert J J, et al. Risk of cancer in children with AIDS. JAMA,2000,284 : 205 -209.
7Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HI-IV8 associated diseases, part 1 : epidemiology,environmental predispositions, clinical manifestations, and therapy.Lancet Infect Dis, 2002, 2:281-292.
8Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi' s sarcoma and non-Hodgkin' s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst, 2002, 94:1204-1210.
9Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumors in developed and developing countries. Eur J Cancer,2001,37: 1188-1201.
10Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi' s sarcoma. Science, 1994,266 : 1865-1869.
